Older adults with cancer respond just as well as younger patients to immune checkpoint inhibitors despite age-related immune system differences, according to a study by researchers from the Johns Hopkins Kimmel Cancer Center and its Bloomberg~Kimmel Institute for Cancer Immunotherapy, and the Johns Hopkins Convergence Institute.
from Medical Xpress - latest medical and health news stories https://ift.tt/mroIKng
